Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has issued an announcement.
Guangzhou Baiyunshan Pharmaceutical Holdings has confirmed that its subsidiary GP Fund II has formally entered into a partnership agreement with GP Capital and Guangkai Fund to establish GP Guangkai Fund, with the terms unchanged from those previously disclosed. The company noted that the separate partnership agreement to set up GP Liwan Fund has not yet been signed and pledged to update the market once it is completed, while cautioning shareholders and potential investors to exercise care when dealing in its securities until the remaining transaction progresses.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is a Hong Kong-listed joint stock company based in Guangzhou, China, operating in the pharmaceutical industry. The group is involved in the production, distribution and investment management of pharmaceutical-related businesses, using fund platforms such as GP Fund II to pursue strategic investments within the healthcare and related sectors.
YTD Price Performance: 5.55%
Average Trading Volume: 1,253,978
Technical Sentiment Signal: Buy
Current Market Cap: HK$44.35B
Learn more about 0874 stock on TipRanks’ Stock Analysis page.